|
management
E. Michael Egan
President, Chief Executive Officer and
Member of
TransMolecular, Inc. Board of Directors
Michael Egan joined TransMolecular in July 2005. Mr. Egan has
an extensive background in the areas of corporate development,
product sales and scientific research. He also has experience
establishing partnerships with global pharmaceutical corporations,
including Centocor, Eli Lilly, Genzyme, Merck and Sandoz. From
2003 until July 2005, he served as Senior Vice President of Commercial
Development for GenVec, Inc. (Nasdaq:GNVC), a clinical-stage biopharmaceutical
company developing gene-based medicines to treat cancer, heart
disease and ophthalmic disorders. Prior to this position, Mr.
Egan was Chief Operating Officer of Diacrin, Inc., a biotechnology
company developing cell transplantation technology for treating
human diseases. Over a ten-year period with Diacrin, Mr. Egan
moved nine product candidates from research to clinical development
and was a key member of the management team involved in Diacrin’s
initial and follow-on public offerings. He held the position of
Senior Vice President, Corporate Development at Diacrin from 1993
to 2001. He joined Diacrin from Repligen, where he held various
executive positions of increasing responsibility from 1983 to
1993. Prior to joining Repligen, Mr. Egan was a laboratory supervisor
at Dana-Farber Cancer Institute, Division of Medicine. He has
served as a member of the Board of Directors of Repligen Clinical
Partners, LP, and as the Secretary/Treasurer of Repligen Sandoz
Research Corporation. Additionally, Mr. Egan has served as a member
of the Diacrin/Genzyme, LLC, and GenVec/Terumo collaboration steering
committees.
Mr. Egan earned his B.S. in biology from Boston
College and a Certificate of Special Studies in Administration
and Management from Harvard University.
Jonathan B. Lloyd Jones
Vice President of Finance
Jonathan B. Lloyd Jones joined TransMolecular in
March 2006 and is responsible for the company’s financial
and controllership functions, information technology and operations
management. He brings more than 20 years of financial management,
accounting and business development experience to the company.
Mr. Lloyd Jones joined TransMolecular from Genzyme where he was
Senior Director of Corporate Development. At Genzyme, he was responsible
for negotiating multi-million dollar acquisition and in-licensing
opportunities, as well as sourcing opportunities, leading corporate
due diligence efforts, and executing valuation and market analysis
on major investments, including Sangstat, Geltex and Biomatrix.
Mr. Lloyd Jones developed Genzyme’s Opportunity Analysis
Process for conducting due diligence and valuation exercises.
At various times he headed Genzyme’s Business Analysis,
Valuation & Modeling and Commercial Assessment groups. Prior
to his tenure with Genzyme, Mr. Lloyd Jones was Manager of Operations
and Finance at The Royal Bank of Scotland (Nassau) Ltd. a registered
Private Bank and Trust Company within The Royal Bank of Scotland
Group. In this position, he was responsible for all financial,
management and regulatory reporting, banking operations and information
technology. From 1981 to 1986, Mr. Lloyd Jones was a senior auditor
for member firms of Ernst & Young and Deloitte Touche Tohmatsu.
Mr. Lloyd Jones has been an invited speaker at the
Regulatory Affairs Professionals Society and Food And Drug Law
Institute and BIO 2000.
He is a Chartered Accountant and holds a M.B.A.
with a dual major in strategic management and finance from The
Wharton School at the University of Pennsylvania and a B.S. in
business studies from The University of Bradford in England.
Dr. Alison M. O’Neill
Vice President of Medical Affairs
Alison M. O’Neill, M.D. joined Transmolecular
in April 2006. She is responsible for the company’s medical
affairs activities and will provide leadership and support for
is cancer therapy development areas. Dr. O’Neill brings
more than 15 years of experience in treating patients with neurologic
and neuro-oncologic diseases, as well as conducting clinical research
studies on cancer and brain tumor therapies.
Prior to joining Transmolecular, Dr. O’Neill
was on faculty at the Massachusetts General Hospital in the Pappas
Center for Neuro-Oncology. She was involved in early clinical
work with TM-601 while on faculty at the University of Alabama
at Birmingham, where she served as clinical director of the Brain
Tumor Treatment and Research Program, and director of the Neurology
Residency Training Program.
Dr. O’Neill received her M.D. from the University
of Chicago Pritzker School of Medicine and completed her neurology
residency and training at the University of Michigan Hospital.
Her fellowship training in neuro-oncology was completed at Memorial
Sloan Kettering Cancer Center in New York. She is certified by
the American Board of Psychiatry and Neurology and has received
certification in imaging interpretation from the American Society
of Neuroimaging.
Susan Stewart
Vice President, Regulatory Affairs
Ms. Stewart joined TransMolecular in November 2005 to oversee
regulatory affairs and strategic planning. She brings more than
17 years of regulatory affairs and quality assurance experience
in product development and commercialization of products for treatment
of cardiovascular, oncologic, renal, immune diseases, orthopedics
and neurological disorders. From 2001 to 2005, she was Vice President
of Regulatory Affairs for Genzyme Corporation; from 2004 to 2005,
she also served as Vice President of Quality and Regulatory Affairs
for MG Biotherapeutics, a joint venture of Medtronic Inc. and
Genzyme. Ms. Stewart also was the regulatory lead for Genzyme
collaborations with Diacrin, Inc., Cambridge Antibody Technologies,
Dyax, Inc. and Medtronic. Her commercial product experience includes
global registration and management of Renagel®, Synvisc®,
Carticel® and Thyrogen®. Prior to joining Genzyme in 1994,
she was Quality Assurance Supervisor for Abbot Laboratories. Ms.
Stewart earned a B.A. from Annhurst College and is both U.S. and
European Union Regulatory Affairs Certified by the Regulatory
Affairs Professionals Society.
Abdellah Sentissi, Ph.D.
Vice President, Manufacturing and Quality Systems
Dr. Sentissi joined TransMolecular in November 2005 to develop
and manage manufacturing and quality systems. Dr. Sentissi brings
more than 20 years of experience creating and managing manufacturing
and quality systems for biotechnology companies. From April 2005
to November 2005, he was Vice President of Quality Systems at
Biovest International, Inc. From 1995 to 2005, he was Vice President
of Quality Systems at GenVec, Inc. where he was responsible for
all quality assurance and control functions, as well as process
validation and optimization for clinical trials through Phase
III. Prior to joining GenVec, he held the positions of Director
of Quality Control, Quality Assurance and Technical Affairs at
Endocon and Chief of the Quality Control Laboratories at The Massachusetts
Biologic Laboratories in Boston.
Dr. Sentissi earned his B.S. in pharmacy from the
University Paul Sabatier, Toulouse, France and a Ph.D. in clinical
chemistry from Northeastern University. He also holds multiple
certifications in medical pathology, immunology, hematology and
parasitology from the University Paul Sabatier and the School
of Pharmacy of Montpellier, France.
Amy Bock
Senior Director, Clinical Operations
Ms. Bock joined TransMolecular in November 2005 and is responsible
for working on new and existing cancer drug development and commercialization
efforts. Ms. Bock brings 19 years of biotechnology experience
in clinical drug development. From 2002 to 2005, Ms. Bock was
the Director of Clinical Research in Genzyme’s Clinical
Strategic Development Group where she was responsible for multiple
operational and technical clinical research functions. From 1998
to 2002, Ms. Bock was Genzyme’s Director of Clinical Research
of Molecular Oncology where she oversaw the gene therapy and cell
based oncology clinical programs. From 1995 to 1998, Ms. Bock
was Genzyme’s Associate Director of Clinical Research. In
this role, she managed the clinical aspects of a strategic alliance
with an oncology pharmaceutical company overseeing the solid tumor
indications in the U.S. and a hematologic malignancy clinical
program in Europe. Upon joining Genzyme in 1991, Ms. Bock oversaw
the clinical drug development of the company’s first major
product, Cerezyme®, approved for treatment of Gaucher Disease.
Prior to joining Genzyme, Ms. Bock held clinical research positions
with Pfizer and the Dana Farber Cancer Institute.
Ms. Bock earned a B.S. in biological psychology
from Pine Manor College and has conducted post graduate work in
cancer biology and immunology at Harvard and graduate studies
towards a degree in public health.
Douglas Jacoby, Ph.D.
Senior Director, Research & Development
Dr. Jacoby joined TransMolecular in November 2005. He is responsible
for identifying new cancer opportunities using pre-clinical models
and discovering new cancer drug mechanisms of TM-601, a synthetic
version of chlorotoxin. Dr. Jacoby brings more than 12 years of
research and development experience in oncology, cellular and
molecular therapies. From 2003 to 2005, he held the position of
Director of Research at GenVec, Inc. In this role, he worked on
the company’s oncology program to demonstrate biological
activity of treatment and determine the mechanism of action in
animal models and patients. From 1999 to 2003, Dr. Jacoby was
the Director of Research at Diacrin. His research background includes
successful translation of product candidates into clinical studies
in the areas of neurodegenerative diseases, stroke, spinal cord
injury and heart failure.
Dr. Jacoby earned an A.B. in biology from
Kenyon College and received his Ph.D. in biochemistry from the
University of Minnesota.
|
